Notably, patients with pre-existing endothelial dysfunction (e.g., diabetes or hypertension) exhibit heightened vulnerability to anti-VEGF/VEGFR cardiovascular toxicity [85], highlighting the imperative for personalized risk stratification and enhanced cardiovascular surveillance. This evidence concerns the gene VEGFA and endothelial dysfunction.